What Is Vasopressin? Benefits, Research & Safety
A hormone essential for water balance and blood pressure regulation, also involved in social behavior and stress responses.
UK summary: Endogenous hormone. Synthetic analogues (vasopressin itself for vasopressor / GI bleeding use; desmopressin for diabetes insipidus and nocturnal enuresis) are UK prescription-only medicines. Prohibited under WADA S5 (diuretics / masking agents).
Quick Facts
Overview
Vasopressin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous hormone. Synthetic analogues (vasopressin itself for vasopressor / GI bleeding use; desmopressin for diabetes insipidus and nocturnal enuresis) are UK prescription-only medicines. Prohibited under WADA S5 (diuretics / masking agents).
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
- EU: Approved for similar indications across member states.
- Notes: Vasopressin and analogues have well-established approved uses. Desmopressin is widely available. Use for behavioural modification or social enhancement is not approved and remains investigational.
05Approved medical uses
- Diabetes insipidus (desmopressin — MHRA-licensed POM).
- Nocturnal enuresis (desmopressin — licensed POM).
- Vasopressor support in shock (vasopressin IV — hospital use).
06Unapproved / promotional claims
- 'Memory peptide' supplements.
- Social-cognition enhancer for healthy adults.
07Common internet claims
- Nasal-vasopressin marketed by biohacker forums as a memory-enhancing nootropic.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Vasopressin supplements improve memory or focus” | E | No | High | Native vasopressin is degraded orally; nasal vasopressin is a UK POM and not appropriate for self-administration. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Hyponatraemia risk (especially with fluid intake combined with desmopressin).
- Cardiovascular effects (BP, vasoconstriction).
- Contraindications include cardiovascular disease, hyponatraemia, SIADH.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
14EU legal position
Approved for similar indications across member states.
15What this page cannot tell you
- Whether a grey-market nasal-vasopressin product contains the labelled compound at the labelled concentration.
- Whether off-label cognitive-enhancement use is safe long-term.
16Last reviewed
17Citation quality score
18Research gaps
- Cognitive-enhancement RCTs in healthy adults are limited; replication poor.
19Safer alternatives / established care pathways
- GP review for any genuine memory or focus concern.
- Adult ADHD assessment if attention is the issue.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is vasopressin (or desmopressin) appropriate for my situation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Effective treatment for central diabetes insipidus (as desmopressin)
- 2Management of nocturnal enuresis/bedwetting (desmopressin)
- 3Treatment of von Willebrand disease (desmopressin)
- 4Vasopressor support in septic shock
- 5Cardiac arrest protocols
- 6Research into social behaviour modulation
- 7Potential applications in psychiatric conditions (investigational)
Claim vs Evidence
How popular claims about Vasopressin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Vasopressin supplements improve memory or focus” | E | No | High | Native vasopressin is degraded orally; nasal vasopressin is a UK POM and not appropriate for self-administration. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Varies greatly by indication and analogue used |
| Frequency | Indication-dependent; from once daily to continuous infusion |
| Duration | Chronic for diabetes insipidus; acute for critical care |
| Notes | Vasopressin and its analogues (especially desmopressin) have established medical uses. Use must be under medical supervision with appropriate monitoring. Water intake restriction may be necessary to prevent water intoxication. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous (critical care, severe diabetes insipidus)
- Subcutaneous (some protocols)
- Intranasal (desmopressin for diabetes insipidus, bedwetting)
- Oral (desmopressin tablets available)
| Half-Life | Stability |
|---|---|
| 10-20 minutes in plasma (vasopressin); longer for desmopressin | Injectable solutions per manufacturer specifications; desmopressin formulations have defined stability |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Water retention
- Headache
- Nausea
- Abdominal cramps
- Nasal congestion (intranasal route)
- Hypertension (vasopressin)
Rare Risks & Concerns
- Water intoxication and hyponatraemia (serious)
- Seizures from hyponatraemia
- Cardiac ischaemia (vasoconstriction)
- Allergic reactions
Contraindications
- Conditions with fluid/electrolyte imbalances
- Coronary artery disease (relative)
- Hyponatraemia
- Polydipsia or inappropriate thirst mechanisms
UK & EU Regulatory Context
🇬🇧 United Kingdom
Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
🇪🇺 European Union
Approved for similar indications across member states.
Clinical Studies Summary
DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.
The remaining authors declare no competing financial interests. A complete list of the members of the SYMPHONY consortium appears in “Appendix.
Central diabetes insipidus (vasopressin deficiency) after surgery for pituitary tumours: a systematic review and meta-analysis.
Following TSS, a small proportion of patients with pituitary adenoma have permanent AVP-D (2%), but prevalence reaches 30% in ones with craniopharyngioma and 14% in those with RCC. Diagnostic criteria for post-operative AVP-D remain variable affecting reported rates of this condition.
Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.
Administration of non-adrenergic vasopressors was significantly associated with reduced mortality in patients with septic shock. However, no single agent achieved statistical significance in separate analyses.
Effect of vasopressin injection technique on ovarian reserve during laparoscopic cystectomy of ovarian endometriomas: a systematic review and meta-analysis of randomized controlled trials.
Vasopressin injection during laparoscopic cystectomy of ovarian endometriomas is effective in reducing blood loss amount and frequency of coagulation, as well as protecting the ovarian reserve. More trials are encouraged to confirm our findings.
THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.
The results of this network meta-analysis suggest that norepinephrine plus dobutamine is associated with a lower risk of 28-day mortality in septic shock patients than other vasoactive medications, and the use of dopamine is associated with a higher risk of 28-day mortality due to septic shock than norepinephrine, terlipressin, and vasopressin.
Therapeutic effects of vasopressin on cardiac arrest: a systematic review and meta-analysis.
Our study failed to demonstrate increased benefit from vasopressin with or without epinephrine compared with the standard of care. However, vasopressin as a part of VSE is associated with the improvement of ROSC in patients with IHCA, and the benefit on mid-term survival or mid-term good neurological outcome is uncertain.
Registered Trials & Regulatory Status
17 of 23 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Systematic Adjunction of Vasopressine in Septic Shock
Status: Not Yet Recruiting · 120 participants · Assistance Publique Hopitaux De Marseille
Conditions: Septic Shock
Intracervical Vasopressin
Status: Recruiting · 50 participants · Prisma Health-Upstate
Conditions: Retained Products of Conception
Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator
Status: Terminated · 2 participants · The Cleveland Clinic
Conditions: Shock, Septic
Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls
Status: Recruiting · 42 participants · University Hospital, Basel, Switzerland
Conditions: Arginine Vasopressin Deficiency, Central Diabetes Insipidus, Oxytocin Deficiency
Vasopressin in the Elderly: Physiological Changes in Neuroendocrine Function and Urinary Secretion in Healthy Aging
Status: Completed · 32 participants · University Hospital, Basel, Switzerland
Conditions: Healthy Ageing
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
Status: Recruiting · 304 participants · Assistance Publique - Hôpitaux de Paris
Conditions: Acute Kidney Injury Post Liver Transplantation
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
Status: Recruiting · 2,800 participants · Hospital do Coracao
Conditions: Septic Shock
Norepinephrine Equivalent Dose of Vasopressin, Phenylephrine and Epinephrine in Septic Shock
Status: Recruiting · 100 participants · Sanjay Gandhi Postgraduate Institute of Medical Sciences
Conditions: Septic Shock
Registry of Patients in Shock Treated With Vasopressin
Status: Unknown · 500 participants · Hospital Universitario 12 de Octubre
Conditions: Vasopressin Causing Adverse Effects in Therapeutic Use, Shock, Vasopressor Adverse Reaction
Dexmedetomidine and Vasopressin in Septic Shock
Status: Unknown · 260 participants · Mansoura University
Conditions: Sepsis, Septic Shock
Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy
Status: Unknown · 387 participants · Al-Azhar University
Conditions: Uterine Surgery
Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair
Status: Completed · 30 participants · Zagazig University
Conditions: Cesarean Section Complications
Adverse event reports (FDA FAERS)
- drug ineffective1,322
- hypotension546
- off label use529
- cardiogenic shock408
- sepsis407
- multiple organ dysfunction syndrome389
- condition aggravated374
- toxicity to various agents330
- acute kidney injury327
- stress312
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Vasopressin?
Source research-grade Vasopressin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Vasopressin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is vasopressin (or desmopressin) appropriate for my situation?
UK regulatory & safety context
Related Peptides
Oxytocin
A natural hormone and neurotransmitter involved in social bonding, childbirth, lactation, and emotional regulation with therapeutic applications.
Learn moreACTH
A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.
Learn moreVIP
A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.
Learn more